---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-096478"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-08-14T12:00:49+00:00"
generated_at: "2026-08-14T12:05:39.870583+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics reports Q3 FY2026 results; FDA-approved LYTENAVA launch planned by end of 2026

## Summary
- Net loss $20.3M ($0.15/share) vs $20.2M ($0.55/share) YoY; adjusted net loss $10.9M ($0.09/share) vs $15.8M ($0.44/share).
- Cash $11.2M at June 30, 2026; subsequent public offering raised ~$51.1M net from 55.6M shares at $0.99.
- FDA approved LYTENAVA (bevacizumab-vikg) for wet AMD; U.S. launch planned before end of calendar 2026.
- Management sees potential to exceed $500M annual U.S. sales by 2030; HCPCS code application by Oct 1, 2026.
- European expansion: Germany, Austria, UK; Netherlands launch later 2026; Switzerland partner Mediconsult launch 2027.

## SEC filing metadata
- accession: 0001104659-26-096478
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-08-14T12:00:49+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/0001104659-26-096478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-096478
- JSON: https://secwatch.observer/filing/0001104659-26-096478.json
- Plain text: https://secwatch.observer/filing/0001104659-26-096478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.